The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 18, 2020
Filed:
Aug. 10, 2017
Applicant:
Nanjing Transthera Biosciences Co. Ltd., Nanjing, Jiangsu, CN;
Inventor:
Frank Wu, Nanjing, CN;
Assignee:
Nanjing TransThera Biosciences Co. Ltd., Nanjing, CN;
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/12 (2006.01); A61K 31/517 (2006.01); C07D 401/12 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); A61P 35/00 (2006.01); C07D 487/08 (2006.01); A61P 35/02 (2006.01); C07D 413/14 (2006.01); A61K 31/5377 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 487/08 (2013.01);
Abstract
Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R, R, R, R, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.